Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials
Date
2017-01
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Springer Verlag
Abstract
In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer's disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Brosch, J. R., Farlow, M. R., Risacher, S. L., & Apostolova, L. G. (2017). Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials. Neurotherapeutics, 14(1), 62–68. http://doi.org/10.1007/s13311-016-0490-y
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Neurotherapeutics
Rights
Publisher Policy
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Final published version